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Background: Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers, and reliable
biomarkers are desirable. The present investigation assesses our ability to identify tumor relevant proteins from
NSCLC tissue interstitial fluid (TIF).
Methods: Paired TIF was collected from three NSCLC patients at the time of surgery, and resolved by
two-dimensional gel electrophoresis and in-gel digestion for proteomic analysis. Differentially expressed spots were
extracted from the two-dimensional gel and characterized by high-performance liquid chromatography-tandem
mass spectrometry. Then, ELISA was used to verify the expression of peroxiredoxin 1 (PRDX1) in TIF of patients with
NSCLC and benign lung disease. Finally, the relationship between expression of PRDX1 and clinicopathological
features was determined.
Results: Comparative proteomic analysis showed 24 protein spots were differentially expressed with significant
changes, including 11 upregulated proteins and 13 downregulated proteins. Of these, PRDX1 was selected for
validation in TIF by Western blot and expression of PRDX1 was confirmed to be upregulated in tumor TIF. It was
also demonstrated that PRDX1 was significantly elevated in 40 NSCLC patients with a mean level of 36.0 ng/mL
compared to 6.26 ng/mL from 20 patients with benign lung disease. A significant correlation was found between
the high level of PRDX1 expression and lymph node metastasis and tumor differentiation.
Conclusions: PRDX1 might be correlated with lymph node metastasis and differentiation, and its elevated
expression in TIF may be an adverse biomarker for patients with NSCLC. PRDX1 may be attributed to the malignant
transformation of NSCLC, and attention should be paid to a possible target for therapy.
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Lung cancer is the most common cause of cancer mor-
tality in the world, and its incidence is steadily increas-
ing [1]. Non-small cell lung cancer (NSCLC) accounts
for more than 80% of all lung cancers. Most NSCLC
patients are diagnosed at an advanced stage, and a variety
of comprehensive treatments failed to significantly prolong
the survival time [2]. Arising from the observation that
early-stage disease is amenable to and may be cured by
surgical resection, early detection of NSCLC would
significantly improve patient clinical outcome [3]. However,* Correspondence: li51487@163.com; sl_cheng@mail.xjtu.edu.cn
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reproduction in any medium, provided the orthere are currently no biomarkers to enable reliable
screening for NSCLC.
Currently, the most accurate diagnostic test is a histo-
logical examination of a tissue biopsy. A less invasive
test from a readily available biofluid such as serum
would be greatly beneficial. Unfortunately, serum is an
extremely complex biofluid containing high-abundant
proteins and differential quantification of potential bio-
markers. In particular, potential biomarkers are likely to
be present at relatively low abundance for early stage
malignancies [4]. Tissue interstitial fluid (TIF) is another
sample that has gained increasing attention as a sub-
strate from which candidate protein biomarker discovery
can be made. The production of TIF results from build-
up of fluid derived from cell secretions due to a lack of a
vascular and lymphatic system within the tumor [5].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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may be a rich source of tumor-specific biomarkers. Despite
its potential value as a source of tumor biomarkers, repre-
sentative catalogs of TIF proteomes of NSCLC are lacking.
In the current study, TIF was collected from patients
diagnosed with NSCLC with matched non-tumor adjacent
tissue samples from operation. These TIF samples were
analyzed by liquid chromatographytandem mass spec-
trometry (LC-MS/MS). Several proteins were identified
as significantly elevated in abundance in tumor TIF, in-
cluding peroxiredoxin 1 (PRDX1). The relative abundance
of PRDX1 was verified in TIF by Western blot analysis.
Furthermore, PRDX1 was found to be elevated in the TIF
of patients diagnosed with NSCLC compared to that in
benign lung disease, as determined by ELISA.
Methods
Patients
NSCLC patients who were confirmed by pathology were
collected in the Second Affiliated Hospital of Xi’an Jiaotong
University from 2009 to 2010, and also received surgical
treatment. Histological classification and differentiation
grade were conducted according to 1999 WHO histological
classification standards of lung cancer; staging was carried
out according to newly revised TNM staging criteria
of the International Union against Cancer in 2009. The
Institutional Ethics Committee approval for this project
was obtained from Second Affiliated Hospital, Medical
School, Xi’an Jiaotong University. All the tumor samples
used contained more than 50% tumor cells, and were stored
at −80°C before use. A total of 40 paired samples were col-
lected, and three tumor samples and three non-tumor adja-
cent samples were randomly chosen from the tissue archive,
and pooled separately. For ELISA assay, samples of 20
patients with benign lung disease were also collected.
Tissue interstitial fluid collection and processing
The TIF collection was carried out as described previously
[6]. Briefly, within 30 minutesof resection, approximately
250 mg of tumor and non-tumor adjacent tissue (NAT)
from NSCLC patients was dissected into small pieces
(1 to 3 mm3), placed into a 6-well plate containing 5 mL
PBS and washed for 5 minutes. Tissues were transferred to
a microcentrifuge tube containing 0.8 mL fresh PBS and
incubated for 1 hour at 37°C to harvest the TIF. The TIF
was transferred to a new microcentrifuge tube, centrifuged
at 1000 rpm for 2 minutes at 4°C and supernatant was
collected. Samples were further centrifuged at 5,000 rpm
for 20 minutes.
Samples were then subjected to immunodepletion
using the Multiple Affinity Removal System (Hu-14, Agilent
Technologies, Inc., Santa Clara, CA, USA) according to
the manufacturer’s protocol. Proteins were extracted from
immunodepleted TIF using a buffer consisting of 7 M urea,2 M thiourea, 4% CHAPS, 2% NP-40, 2% pharmalyte,
5 mM PMSF, 1% Triton X-100, 100 mM DTT, and 0.5 mM
EDTA, and centrifuged for 1 hour at 4,000 rpm. The super-
natant was precipitated with acetone and dried. Protein
concentrations were determined using the Bradford assay.
All samples were stored at −80°C prior to electrophoresis.
Two-dimensional gel electrophoresis
First-dimension isoelectric focusing was performed at
20°C for 30,000 VhT using IPGphorTM Isoelectric Focusing
Unit (Amersham Pharmacia Biotech AB, Uppsala, Sweden).
The second-dimension gel electrophoresis was performed
using 12.5% gradient SDS polyacrylamide gels with buffer
running solutions containing 1.5 M Tris and 10% SDS.
Gels were stained with 0.2% (w/v) silver nitrate [6].
ScanMaker8700 (Amersham Pharmacia Biotech AB)
was used for scanning of gels and image analysis soft-
ware (Image Master 2D Platinum Software 5.0, Geneva
Bioinformatics, Geneva, Switzerland) was used to construct
average gels from three independent experiments and a
comparison between those average gels was performed.
High-performance liquid chromatography-tandem mass
spectrometry
After digestion of interested differently expressed spots,
an HPLC system (Surveyor, ThermoFinnigan, San Jose,
CA, USA) was applied. Peptides were eluted by using a
gradient from buffer A (0.1% formic acid) to buffer B
(90% vol/vol acetonitrile, 0.1% formic acid). The HPLC
column eluent was eluted directly into the electrospray
ionization source of a LCQ-Deca ion trap mass spec-
trometer (ThermoFinnigan). Automated peak recogni-
tion, dynamic exclusion, and daughter ion scanning of
the top two most intense ions were performed using the
Xcalibur software (ThermoFinnigan, San Jose, CA, USA)
[7]. Spectra were scanned over the range 400 to 2,000
mass units. MS/MS data were analyzed using SEQUEST
database a computer program that allows the correlation
of experimental data with theoretical spectra generated
from known protein sequences [8]. All matched peptides
were confirmed by visual examination of the spectra, and
all spectra were searched against the latest version of the
public non-redundant protein database of the NCBI
(http://www.ncbi.nlm.nih.gov) or SWISS-PROT (http://
web.expasy.org/docs/swiss-prot_guideline.html).
Western blot
Total protein from each sample (10 mg) was separated on
12% polyacrylamide gel and then transferred electrophor-
etically onto polyvinylidene difluoride membranes. After
blocking for 1 hour with blocking buffer (1 × PBS, 0.5%
Tween-20 with 5% non-fat dry milk), the membranes were
incubated overnight at 4°C with antibodies against PRDX1
(Abcam, Cambridge, MA, USA; 1:500) The primary
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conjugated secondary antibodies (goat anti-rabbit or mouse
immunoglobulin G; Santa Cruz Biotechnology, CA, USA).
Visualization of the immunoreactive proteins was ac-
complished by use of ECL Plus reagents (Amersham
Biosciences, Little Chalfont, UK) and exposed to X-ray
film. β-actin was used as a loading control.
ELISA
The levels of abundance of PRDX1 were measured using
the peroxiredoxin 1 Human ELISA kit (BioVendor, Candler,
NC, USA) according to the manufacturer’s instructions.
TIF samples from patients with NSCLC and benign lung
pathology were diluted 1:4 prior to measurement and
were assayed simultaneously in duplicate. Serial dilu-
tions of PRDX1 standard were assayed in parallel with
TIF samples. The optical density was plotted against
standard PRDX1 concentrations to generate the stand-
ard curve according to the manufacturer’s protocol. A
non-parametric Wilcoxon rank-sum test was used to
determine the significance of the difference between the
median PDRX1 quantities in TIF of patients with benign
lung pathology versus patients with NSCLC.
Statistical analysis
To avoid including in the data analysis proteins with no
real change in expression, we selected only spots with aFigure 1 Differentially expressed proteins in tissue interstitial fluid of
electrophoresis gel is representative of all the tissue interstitial fluid sample
patients. Spot number reflects the number listed for the specific protein in
on the image. (A) Non-tumor adjacent tissue; (B) tumor.fold-change higher than 2 to be considered for statistical
analysis. The student’s t-test was used to compare the west-
ern blot and ELISA results. To investigate the association
with clinicopathologic features, PDRX1 expression values
were dichotomized into low and high groups using the me-
dian expression value within the cohort as a cutoff. A Fish-
er’s exact text was used to analyze the relationship between
expression levels of PDRX1 and various clinicopathologic
characteristics. The difference was considered statistically
significant if the P-value was less than 0.05.
Results
Two-dimensional gel electrophoresis and the analysis of
gel images
In order to identify proteins associated with NSCLC
development, we compared two-dimensional gel patterns
of tumor and NAT TIF proteomes. NAT samples were
obtained from more than 5 cm away from the tumor mar-
gin of the NSCLC. The samples were immunodepleted of
serum albumin and immunoglobulin G for minimization
of sample bias. The resulting images were analyzed
using PDQUEST software (Bio-Rad, Hercules, CA, USA).
Typical two-dimensional gel electrophoresis proteome
spot patterns of tumor TIF and NAT TIF are shown in
Figure 1. Under the same experimental conditions, six
gels(three for tumor TIF and three for NAT TIF) were
analyzed. In the two-dimensional gel electrophoresisnon-small cell lung cancer biopsies. The two-dimensional
s, since it has been obtained by pooling tissue interstitial fluid of all
Table 1. Molecular weight (kDa) and isoelectric values (pI) are shown









48 LINE-1 type transposase domain-containing protein 1 (L1TD1) 38 46 98789 Down/13.7
90 Serotransferrin 49 99 77014 Down/3.9
94 Heat shock protein HSP 90-beta 39 50 83212 Up/3.1
103 Complement C3 33 96 187030 Down/6.1
116 Heat shock cognate 71 kDa protein 50 106 70854 Up/4.7
122 Heat shock 70 kDa protein 1A/1B 51 122 70009 Down/8.1
156 Vinculin 23 39 123722 Down/3.1
168 Fibrinogen gamma chain 54 103 51479 Up/3.9
170 Fibrinogen beta chain 45 81 55892 Up/2.4
193 Tubulin-specific chaperone E 34 48 59309 Down/7.7
204 GAS2-like protein 1 37 45 72672 Down/5.7
227 Alpha-enolase 50 68 47139 Up/4.3
230 Zinc finger protein 879 42 49 64536 Up/2.7
272 Putative uncharacterized protein FLJ46541 56 49 18178 Down/2.3
349 Zinc finger protein 658B 52 50 94270 Down/3.4
364 ADP-ribosylation factor-related protein 1 71 44 22599 Up/3.5
386 Zinc finger and SCAN domain-containing protein 10 48 42 80336 Down/2.1
390 Serine/threonine-protein kinase ATR 21 49 301172 Down/2.6
403 Glutathione S-transferase P 56 47 23341 Up/3.0
409 Peroxiredoxin-1 37 54 22096 Up/15.0
434 CAP-Gly domain-containing linker protein 3 34 45 59522 Down/7.0
448 Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 28 41 41874 Up/6.1
459 t-SNARE domain-containing protein 1 23 34 55914 Up/4.8
473 Hemoglobin subunit alpha 68 56 15248 Down/4.4
a Protein spot numbers are highlighted in Figure 1.
b Sequence coverage of the matched peptides in protein by NCBInr Database.
c MASCOT score is a parameter that correlates with the quality of the search result on the MASCOT and SWISS-PROT. High scores are indicative of successful,
valid identifications.
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were found to be differentially expressed with changes
in the stain density of two-fold or more, including 11
upregulated proteins and 13 downregulated proteins
(P < 0.05).Figure 2 An example tandem mass spectrum of a peptide. This spectr
high-performance liquid chromatography mass spectrometry.High-performance liquid chromatography-tandem mass
spectrometry
Twenty four differentially expressed spots were identified
by HPLC-MS analysis. All identified different proteins
are shown in Table 1. An example (No.409 as shown inum represents one example of a peptide identified by
Figure 3 A comparison of protein identification results.
Detected proteins were mainly involved in energy metabolism and
signal transduction.
Figure 5 Peroxiredoxin 1is elevated in tissue interstitial fluid
from non-small cell lung cancer patients. Tissue interstitial fluid
from 40 patients diagnosed with non-small cell lung cancer (NSCLC)
and tissue interstitial fluid from 20 patients with benign lung
pathology was evaluated for peroxiredoxin 1 (PRDX) presence and
quantity by ELISA. There was a statistically significant difference
between the mean PDRX levels in the two groups.
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the 24 peptides is shown in Figure 2. The identified
proteins were next categorized into possible functions
according to the classification systems [9]. Detected
proteins were mainly involved in energy metabolism
and signal transduction (Figure 3). Among those proteins
identified, PRDX1 was identified in greater abundance
(an average of 15-fold greater spectral count) in NSCLC
TIF samples as compared to NAT TIF. We therefore
chose PRDX1 as a candidate protein for the following
experiments.
Confirmation of upregulated expression of peroxiredoxin
1 by Western blot and ELISA
We first confirmed the expression of PRDX1 in the NSCLC
and NAT TIF by western blot. The results showed that
PRDX1 was upregulated in NSCLC TIF compared to that
of NAT (Figure 4). Then, we applied ELISA to detect the
expression of PRDX1 in TIF of samples of NSCLC,
NAT and benign lung disease. The mean level of PRDX1
from these 40 NSCLC patients was determined to be
36.0 ± 5.48 ng/mL and 6.26 ± 3.12 ng/mL from the 20
benign lung populations as measured using a commercially
available PDRX1 ELISA (Figure 5). Furthermore, expression
of PRDX1 was significantly related to lymph node me-
tastasis and differentiation (Table 2).Figure 4 Western blot analysis of peroxiredoxin 1 in tissue
interstitial fluid of tumor and non-tumor adjacent tissue.
Western blot analysis revealed markedly upregulated peroxiredoxin 1
(PRDX1)expression in tumor tissue interstitial fluid. β-actin was used
as a loading control.Discussion
Because potential protein biomarkers are more abundant in
the tumor tissue microenvironment than serum, an in-
creased focus in proteomics is to utilize proximal fluids. As
one example of a proximal fluid, TIF has proven to be an
important resource for cancer biomarker discovery). Celis
and colleagues [6] investigated proteins from breast cancer
and normal TIF, where it was demonstrated that proteins
identified by MS-based proteomics could be externally
validated in a tissue microarray containing over 70 breast
carcinoma tissue samples [10]. Furthermore, there are lots
of reports of TIF in renal cell carcinoma, head and neck
squamous carcinoma, and ovarian cancer [4,11,12], but
there is limited research on TIF in NSCLC.
In our analysis, 24 protein spots were identified between
tumor TIF and NAT, including 11 upregulated proteins
and 13 downregulated proteins. Some identified proteins
function as potential tumor-associated proteins. Alpha-
enolase (ENO1), which was found to be over-expressed
in our study, has also been reported to be upregulated
in several types of cancer [13-15]. Furthermore, ENO1
was identified as a tumor antigen in lung cancer with
different proteomic methods by two independent scientific
groups [16,17]. Moreover, its overexpression was associated
with clinical outcomes in lung cancer [17]. Glutathione
S-transferase P (GSTP) is another upregulated protein
in our study. Previous studies revealed there is an asso-
ciation between high levels of GSTP and malignant
diseases and drug-resistant cancer [18].
As the fold of change of PRDX1 was the most significant,
we chose it for confirmation and further experiment.
PRDX1 is a member of the redox-regulating protein family,
Table 2 Relationship between clinicopathologic variables
and the expression status of peroxiredoxin 1
Variables Total PRDX1 P
Low High
Age 0.332
< 60 18 4 14
≥60 22 8 14
Gender 0.697
Male 31 10 21
Female 9 2 7
Smoker status 0.530
Yes 23 6 17
No 17 6 11
Histology 0.808
AC 16 4 12
SCC 23 8 15
ASC 1 0 1
T-stage 0.729
T1-2 24 8 16
T3-4 16 4 12
p-TNM stage 0.677
I-II 22 6 16
III-IV 18 6 12
Lymph node metastasis 0.006
No 20 10 10
Yes 20 2 18
Differentiation 0.004
Poorly differentiated 17 1 16
Highly differentiated 23 11 12
AC, adenocarcinoma; ASC, adenosquamous carcinoma; PRDX1, peroxiredoxin 1;
pTNM, pathological tumor-node-metastasis; SCC, squamous cell carcinoma.
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to its known elevated level of gene expression in numerous
cancers [20-22], including NSCLC [23-25]. PRDX1 presence
in carcinomas is associated with inhibition of apoptosis,
equating to increased tumor survival [20-25]. In addition,
several other peroxiredoxin family members (PRDX2-6)
are thought to be linked to lung cancer [26-28]. Although
much effort has been devoted to the investigation of
PRDX1 function in cultured cells, animal systems and
tissues, no research has been undertaken to evaluate
the value of PRDX1 in TIF in NSCLC.
In the present study, the presence of PRDX1 in TIF
from NSCLC patients was verified by Western blot to
be elevated in abundance in tumor TIF as compared to
NAT TIF. We attempted to determine the levels of
PRDX1 in TIF of samples from malignant or benign lung
disease using a highly validated, commercially available
ELISA. These results demonstrated that patients with
NSCLC had a six-fold elevated level of PRDX1 in theirTIF compared to patients with benign lung pathology
(P < 0.05). Furthermore, expression of PRDX1 was sig-
nificantly related to lymph node metastasis and differ-
entiation. These results suggest that PRDX1, in addition
to serving as a biomarker, may also serve as a thera-
peutic target. Based on the hypothesis that a subset of
TIF proteins represents shed/secreted proteins from the
microenvironment, the TIF proteins may be exchangeable
and detectable within peripheral blood. Thus we will detect
the expression and diagnostic value of PRDX1 in blood
in a further study.Conclusion
In conclusion, we utilized a mass spectrometry based
proteomics workflow to identify tumor specific proteins
from TIF from NSCLC patients. Among the differen-
tially abundant proteins identified from TIF, PRDX1 was
demonstrated to be present in TIF by Western blot and
to be elevated in NSCLC patients by ELISA. Our study
adds further support to the hypothesis that TIF represents
an attractive proximal biofluid for conducting candidate
biomarkers of NSCLC.Consent
Written informed consent was obtained from the patients
for the publication of this report and any accompanying
images.
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